Tim Oldham

CEO and Managing Director at Adalta Ltd

Presenter

AdAlta (ASX: 1AD) is an Australian clinical stage biotechnology company addressing the need for effective cellular immunotherapies for the treatment of solid cancers. CAR-T cell therapies are transforming blood cancer outcomes and Asia/China is fast becoming the leading innovation hub for biotech innovation, especially in CAR-T. Barriers remain to bringing the promise of CAR-T to solid cancers and bringing Asian innovation to the world. AdAlta is solving these challenges by spinning out its ‘East to West’ cellular immunotherapy subsidiary, AdCella, to integrate Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. AdCella in-licenses clinical stage, first in class solid cancer products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies in Australia, positioning each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization. AdAlta has also created two novel protein assets available for partnering: - AD-214 is a first in class fusion protein taking a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of lung an and two successful Phase I clinical studies, AD-214 is available for partnering. -WD-34 is a first in class protein that is the world's first antibody like molecule offering high potency inhibition of malarial parasite invasion with pan-strain efficacy. WD-34 has potential to transform malaria and babesiosis prophylaxis from daily oral medications to single shot seasonal prophylaxis.